MedPath

Shanghai Vitalgen Biopharma Co.,Ltd

Shanghai Vitalgen Biopharma Co.,Ltd logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:5
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (83.3%)
Phase 3
1 (16.7%)

Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy

Phase 3
Not yet recruiting
Conditions
Bietti Crystalline Dystrophy
Inherited Retinal Diseases
Interventions
First Posted Date
2024-11-21
Last Posted Date
2024-11-21
Lead Sponsor
Shanghai Vitalgen BioPharma Co., Ltd.
Target Recruit Count
45
Registration Number
NCT06699108
Locations
🇨🇳

Shanghai Vitalgen Biopharma Co.,Ltd., Shanghai, Shanghai, China

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease

Phase 1
Not yet recruiting
Conditions
Parkinson's Disease
Interventions
First Posted Date
2024-06-28
Last Posted Date
2024-06-28
Lead Sponsor
Shanghai Vitalgen BioPharma Co., Ltd.
Target Recruit Count
39
Registration Number
NCT06480461

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency

Phase 1
Not yet recruiting
Conditions
Aromatic L-amino Acid Decarboxylase Deficiency
First Posted Date
2024-05-29
Last Posted Date
2024-06-03
Lead Sponsor
Shanghai Vitalgen BioPharma Co., Ltd.
Target Recruit Count
16
Registration Number
NCT06432140

A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b

Phase 1
Recruiting
Conditions
Glutaric Aciduria Type I
Glutaric Acidemia Type I
First Posted Date
2024-01-23
Last Posted Date
2024-05-17
Lead Sponsor
Shanghai Vitalgen BioPharma Co., Ltd.
Target Recruit Count
12
Registration Number
NCT06217861
Locations
🇨🇳

The Children's Hospital Zhejiang University Shcool of Medicine, Hangzhou, Zhejiang, China

Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy

Phase 1
Not yet recruiting
Conditions
Bietti Crystalline Dystrophy
First Posted Date
2023-01-23
Last Posted Date
2023-01-23
Lead Sponsor
Shanghai Vitalgen BioPharma Co., Ltd.
Target Recruit Count
12
Registration Number
NCT05694598
Locations
🇨🇳

Shanghai Vitalgen Biopharma Co.,Ltd., Shanghai, Shanghai, China

  • Prev
  • 1
  • 2
  • Next

News

Shanghai Vitalgen Advances VGR-R01 Gene Therapy to Phase 3 Trial for Bietti Crystalline Dystrophy

Shanghai Vitalgen BioPharma has initiated a Phase 3 multicenter randomized controlled trial evaluating VGR-R01 gene therapy in 45 patients with Bietti crystalline dystrophy.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.